These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 20490730

  • 1. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.
    Ieko M, Yoshida M, Naito S, Nakabayashi T, Kanazawa K, Mizukami K, Mukai M, Atsumi T, Koike T.
    Int J Hematol; 2010 Jun; 91(5):776-83. PubMed ID: 20490730
    [Abstract] [Full Text] [Related]

  • 2. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [Abstract] [Full Text] [Related]

  • 3. Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies.
    Martínez-Zamora MA, Tassies D, Carmona F, Espinosa G, Cervera R, Reverter JC, Balasch J.
    J Reprod Immunol; 2010 Nov; 86(2):133-40. PubMed ID: 20594598
    [Abstract] [Full Text] [Related]

  • 4. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL, Roubey RAS, Kitzmiller KJ, Zhou D, Nagaraja HN, Mulvihill E, Barbar-Smiley F, Ardoin SP, Wu YL, Yu CY.
    Front Immunol; 2019 Nov; 10():885. PubMed ID: 31134052
    [Abstract] [Full Text] [Related]

  • 5. Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis.
    Lambrianides A, Turner-Stokes T, Pericleous C, Ehsanullah J, Papadimitraki E, Poulton K, Ioannou Y, Lawrie A, Mackie I, Chen P, Latchman D, Isenberg D, Rahman A, Giles I.
    Arthritis Rheum; 2011 Nov; 63(11):3512-21. PubMed ID: 21739425
    [Abstract] [Full Text] [Related]

  • 6. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U, Yayla ME, Ateş A, Okatan İE, Yurteri EU, Torgutalp M, Keleşoğlu ABD, Turgay TM, Kınıklı G.
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [Abstract] [Full Text] [Related]

  • 7. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses.
    Radway-Bright EL, Ravirajan CT, Isenberg DA.
    Rheumatology (Oxford); 2000 Apr; 39(4):427-31. PubMed ID: 10817777
    [Abstract] [Full Text] [Related]

  • 8. [Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome].
    Reshetniak TM, Patrushev LI, Stukacheva EA, Miroshnikov AI, Tikhonova TL, Nasonov EL, Alekberova ZS.
    Ter Arkh; 2000 Apr; 72(5):34-8. PubMed ID: 11109617
    [Abstract] [Full Text] [Related]

  • 9. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C.
    Lupus; 2004 Apr; 13(12):927-33. PubMed ID: 15645748
    [Abstract] [Full Text] [Related]

  • 10. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S, Regnault V, Guillemin F, Kaminsky P, Rat AC, Lecompte T, Wahl D.
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [Abstract] [Full Text] [Related]

  • 11. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC.
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 13. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
    Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, Nikoloudaki M, Pieta A, Flouda S, Parodis I, Bertsias G, Fanouriakis A, Filia A, Boumpas DT.
    Ann Rheum Dis; 2024 Aug 27; 83(9):1132-1143. PubMed ID: 38609158
    [Abstract] [Full Text] [Related]

  • 14. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM.
    Arthritis Rheum; 2004 Aug 27; 50(8):2569-79. PubMed ID: 15334471
    [Abstract] [Full Text] [Related]

  • 15. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome.
    Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GR.
    Br J Rheumatol; 1998 Nov 27; 37(11):1229-32. PubMed ID: 9851275
    [Abstract] [Full Text] [Related]

  • 16. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
    Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, Kiss E.
    Clin Rev Allergy Immunol; 2007 Apr 27; 32(2):131-7. PubMed ID: 17916982
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis.
    Martinez-Zamora MA, Tassies D, Carmona F, Espinosa G, Cervera R, Reverter JC, Balasch J.
    Am J Reprod Immunol; 2009 Dec 27; 62(6):381-9. PubMed ID: 19895374
    [Abstract] [Full Text] [Related]

  • 18. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 19. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome.
    Atsumi T, Khamashta MA, Andujar C, Leandro MJ, Amengual O, Ames PR, Hughes GR.
    J Rheumatol; 1998 Jan 06; 25(1):69-73. PubMed ID: 9458205
    [Abstract] [Full Text] [Related]

  • 20. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome.
    Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V, Sanmarco M, Sampol J.
    Thromb Haemost; 2004 Apr 06; 91(4):667-73. PubMed ID: 15045126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.